Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Oncogene Science Inc.

(ONCS)

Michael Ehrenreich of Ehrenreich & Co. initiated coverage with an "overweight" rating. His recommendation was based

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE